DEVELOPMENT AND ANALYSIS OF A PROGNOSTIC MODEL FOR DNA METHYLATION RISK IN ATHLETIC PATIENTS WITH PAPILLARY RENAL CELL CARCINOMA: THE IMPACT OF PHYSICAL FITNESS

Abstract

Purpose: This study aimed to explore the prognostic significance of DNA methylation expression profiles in papillary renal cell carcinoma (pRCC) among athletic patients, incorporating an analysis of their physical fitness and overall patient survival (OS). Methods: We conducted a bioinformatics analysis, using a retrospective approach, to examine DNA methylation expression profiles alongside clinical data from 217 pRCC patients, including those with a history of athletic activity and high physical fitness, from the Cancer Genome Atlas (TCGA). Through Cox risk regression analysis, methylation loci linked to pRCC prognosis were identified, leading to the development of risk prognostic models. These models were evaluated for their predictive accuracy using Kaplan-Meier survival curves and Receiver Operating Characteristic (ROC) curves in both training and test sets. Data stratification methods were employed to ascertain the model's role as an independent prognostic factor for OS. Results: The study successfully established a 3-DNA methylation risk prognostic model. Patients were categorized into high-risk and low-risk groups based on median risk scores. The model demonstrated significant predictive capability, with patients in the high-risk group showing substantially shorter survival times compared to those in the low-risk group (P<0.005). Further, data stratification confirmed the model as an independent prognostic factor for OS in pRCC patients, including those with athletic backgrounds. Conclusion: The 3-DNA methylation risk prognostic model emerges as a novel prognostic biomarker for pRCC, offering valuable insights into the prognosis of patients, notably those who are athletes or possess high levels of physical fitness. This model underscores the importance of considering DNA methylation patterns in the context of patient lifestyle and fitness level, enhancing personalized treatment and management strategies for pRCC.